Enhancer of zeste homolog 2 (EZH2), as a main component of Polycomb Repressive Complex 2, catalyzes histone H3K27me3 to silence its target gene expression. EZH2 upregulation results in cancer development and poor prognosis of cancer patients. Post-translational modifications (PTMs) are important biological events in cancer progression. PTMs regulate protein conformation and diversity functions. Recently, mounting studies have demonstrated that EZH2 stability, histone methyltransferase activity, localization, and binding partners can be regulated by PTMs, including phosphorylation, O-GlcNAcylation, acetylation, methylation and ubiquitination. However, the detailed molecular mechanisms of the EZH2-PTMs and whether other types of PTMs occur in EZH2 remain largely unclear. This review presents an overview of different roles of EZH2 modification and EZH2-PTMs crosstalk during tumorigenesis and cancer metastasis. We also discussed the therapeutic potential of targeting EZH2 modifications for cancer therapy.

中文翻译：

---

EZH2在癌症中的翻译后修饰

zeste同源物2（EZH2）的增强子，作为Polycomb Repressive Complex 2的主要成分，催化组蛋白H3K27me3使其目标基因表达沉默。EZH2上调导致癌症发展和癌症患者的预后不良。翻译后修饰（PTM）是癌症进展中的重要生物学事件。PTM调节蛋白质构象和多样性功能。最近，越来越多的研究表明EZH2的稳定性，组蛋白甲基转移酶活性，定位和结合伴侣可以通过PTM调节，包括磷酸化，O-GlcNAcylation，乙酰化，甲基化和泛素化。但是，EZH2-PTMs的详细分子机制以及在EZH2中是否存在其他类型的PTMs仍然不清楚。这篇综述概述了EZH2修饰和EZH2-PTM串扰在肿瘤发生和癌症转移过程中的不同作用。我们还讨论了靶向EZH2修饰物用于癌症治疗的治疗潜力。